Allergic bronchopulmonary aspergillosis.
Allergic bronchopulmonary aspergillosis.
复制标题
DOI：
10.4103/ijmr.ijmr_1187_19
复制
发表时间：
2020-06
期刊：
影响因子：
--
通讯作者：
Chakrabarti A
中科院分区：
文献类型：
--
作者：
Agarwal R;Sehgal IS;Dhooria S;Muthu V;Prasad KT;Bal A;Aggarwal AN;Chakrabarti A
变应性支气管肺曲霉病（ABPA）是一种炎症性疾病，由对烟曲霉菌的免疫反应引起的支气管哮喘和囊性纤维化患者的气道定植。常见的临床表现包括难治性哮喘、一过性和一过性肺阴影和支气管扩张。据信，全球约有500万例ABPA病例，仅印度就约有140万例。在专科门诊的哮喘患者中，ABPA的发生率可能高达13%，因此，在治疗支气管哮喘患者时，尤其是在专科门诊，应高度怀疑ABPA。早期诊断和适当的治疗可以延缓（甚至预防）支气管扩张的发生，这表明所有支气管哮喘患者都应进行ABPA筛查，尤其是在胸科门诊。本文就ABPA的发病机制、诊断和治疗的最新进展作一综述。
Allergic bronchopulmonary aspergillosis (ABPA) is an inflammatory disease caused by immunologic reactions initiated against Aspergillus fumigatus colonizing the airways of patients with asthma and cystic fibrosis. The common manifestations include treatment-resistant asthma, transient and fleeting pulmonary opacities and bronchiectasis. It is believed that globally there are about five million cases of ABPA, with India alone accounting for about 1.4 million cases. The occurrence of ABPA among asthmatic patients in special clinics may be as high as 13 per cent. Thus, a high degree of suspicion for ABPA should be entertained while treating a patient with bronchial asthma, particularly in specialized clinics. Early diagnosis and appropriate treatment can delay (or even prevent) the onset of bronchiectasis, which suggests that all patients of bronchial asthma should be screened for ABPA, especially in chest clinics. The current review summarizes the recent advances in the pathogenesis, diagnosis and management of ABPA.